A total of 498 patients , 12-40 years of age , were randomized to receive clindamycin-BP 3.75 % or vehicle in a double-blind , controlled 12-week , 2-arm study evaluating safety and efficacy using inflammatory and noninflammatory lesion counts , Evaluator Global Severity Scores ( EGSS ) and subject self-assessment ( SSA ) .